74.52
+0.32(+0.43%)
Currency In USD
| Previous Close | 74.2 |
| Open | 74.2 |
| Day High | 74.94 |
| Day Low | 72.05 |
| 52-Week High | 83 |
| 52-Week Low | 7.58 |
| Volume | 447,956 |
| Average Volume | 1.11M |
| Market Cap | 3.16B |
| PE | -21.48 |
| EPS | -3.47 |
| Moving Average 50 Days | 58.6 |
| Moving Average 200 Days | 27.43 |
| Change | 0.32 |
If you invested $1000 in Celcuity Inc. (CELC) since IPO date, it would be worth $5,214.84 as of November 08, 2025 at a share price of $74.52. Whereas If you bought $1000 worth of Celcuity Inc. (CELC) shares 5 years ago, it would be worth $12,848.28 as of November 08, 2025 at a share price of $74.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call
GlobeNewswire Inc.
Nov 05, 2025 12:05 PM GMT
MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third qu
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
GlobeNewswire Inc.
Nov 04, 2025 12:05 PM GMT
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
GlobeNewswire Inc.
Oct 18, 2025 8:30 AM GMT
PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolledAdditional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median prog